ClouDr Group (9955) H1 2023 earnings summary

Executive summary

• H1 2023 revenue rose 30.6% YoY to RMB1,802.6m, led by hospital and pharmacy solutions; gross profit increased 22.7% to RMB473.6m.

• Adjusted net loss narrowed 60.2% to RMB58.9m; growth priorities included expanding hospital and pharmacy networks and investing in healthcare AI.

Financial highlights

• Revenue was RMB1,802.6m versus RMB1,379.7m; gross profit was RMB473.6m versus RMB386.0m.

• Operating loss narrowed to RMB154.3m from RMB263.9m; loss for the period fell to RMB159.6m from RMB1,234.7m.

• Adjusted net loss was RMB58.9m versus RMB148.0m; adjusted net loss margin improved to 3.3% from 10.7%.

• Basic and diluted loss per share was RMB0.29 versus RMB11.94.

Outlook and guidance

• Priorities included expanding hospital and pharmacy SaaS networks, growing patient and doctor communities, investing in medical AI, and pursuing partnerships and acquisitions.

• Hospital plans centered on deeper partnerships and pharmaceutical digital-marketing monetization; pharmacy plans emphasized broader SaaS reach, services and supply-chain capabilities.

• Digital marketing services were expected to increase gradually in H2 as delayed SKU collaborations progressed; no full-year numerical guidance was stated.